chronic heart failure

ARCA Biopharma, Inc. (NASDAQ: ABIO) 89.3% HIGHER; today announced that the U.S. FDA has designated as a Fast Track development program the investigation of Gencaro, the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population.

ARCA Biopharma, Inc. (NASDAQ: ABIO) 47.6% HIGHER; today announced that the U.S. FDA has designated as a Fast Track development program the investigation of Gencaro, the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population.

Franklin Electronic Publishers, Inc. (AMEX: FEP) 111% HIGHER; today announced that it has received a copy of a Schedule 13D filed with the SEC relating to a non-binding proposal by Saunders Acquisition Corporation for an all cash acquisition at $2.35 per share. More from the release.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 98.6% HIGHER; At ASCO yesterday, Keryx announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Click here for the full report.